IOVANCE BIOTHERAPEUTICS INC (IOVA)

Company Profile

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 503 full-time employees. The company went IPO on 2008-06-20. The company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, lifileucel, is being developed in advanced, or metastatic or unresectable, melanoma, as well as in other indications. Lifileucel is investigated in two consecutive cohorts in a clinical trial of advanced melanoma patients post-anti-PD-1 therapy, including in a prospectively defined pivotal cohort. The company has initiated Phase III clinical trial of lifileucel in combination with pembrolizumab, TILVANCE-301. The firm is also pursuing registrational strategies for lifileucel in advanced cervical cancer and for its TIL therapy, LN-145, in metastatic non-small cell lung cancer. Its first genetically modified, PD-1 inactivated TIL therapy, IOV-4001, is under Phase I/II clinical trial, IOV-GM1-201.

Company Info

IOVANCE BIOTHERAPEUTICS INC

825 Industrial Road, 4th Floor

San Carlos CALIFORNIA 94070

P: 16502607120

CEO: Maria Fardis

Employees: 503

Website: https://www.iovance.com/